STAT3 and breast cancer: Wang et al. found that impaired IL-6 p-STAT1 and p-STAT3 activation in peripheral T cells was observed at baseline in breast cancer patients who later relapsed compared to patients who did not relapse following standard treatment (Fig. 5A) [19].